Symrise looks to volume growth as pet nutrition prices normalize

Symrise hit global sales of €2.53 billion ($2.91B) in H1 2026, a slight decrease from €2.55 billion ($2.93B) in the first 6 months of 2025.

The Taste, Nutrition & Health segment, which includes its pet food division, generated sales of €1.53 billion ($1.76B). In the same period of last year, sales amounted to €1.52 billion ($1.74B).

This marks an improvement from FY2025, when the segment posted a 2% year-over-year revenue decline, which at the time was attributed to portfolio changes and exchange rate effects. During H1 2026, the company says that foreign exchange effects had a negative €44.1 million ($50.7M) impact on the segment.

While specific H1 2026 figures for the pet food division were not laid out, the company had noted during its FY2025 results that pet nutrition sales were “in line with the market” and benefited from strategic pricing initiatives. 

CEO Jean-Yves Parisot stated that prices in pet nutrition were normalizing and that future growth would be driven primarily by volume.

Regarding profitability, the Taste, Nutrition & Health segment increased adjusted EBITDA to €374.7 million ($431.1M), up 0.6% from €372.4 million ($428.5M) in H1 2025. This resulted in an adjusted EBITDA margin improvement of 10 basis points, reaching 24.5%.

Regional breakdown 

Global organic sales growth stood at 2% from January to July, accelerating to 4.5% in the second quarter. 

Latin America and Asia/Pacific were the strongest drivers of organic growth, posting increases of 7.7% and 5.6%, respectively. EAME remained the largest region by total sales volume, bringing in €1,016.8 million ($1,169.9M), though it experienced an organic decline of 2.7%.

Company-wide adjusted EBITDA reached €553 million ($628.3M).

The Holzminden-based company noted that earnings development was supported by profitable sales growth and efficiency measures, though partially offset by logistics costs tied to Middle East tensions and investments in its ongoing corporate transformation program.

Outlook 

Symrise reaffirmed its full-year 2026 guidance, expecting organic global sales growth of between 2% and 4%. The company anticipates an adjusted EBITDA margin of 21.5% to 22.5%.

“Based on our first half performance and current momentum, we remain confident in delivering our 2026 outlook and creating durable long-term value,” Parisot concludes.